Carson Wealth (CWM LLC)’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-1,361
Closed -$28K 5196
2025
Q1
$28K Sell
1,361
-100
-7% -$2.23K ﹤0.01% 3442
2024
Q4
$33K Buy
1,461
+103
+8% +$2.47K ﹤0.01% 3101
2024
Q3
$33K Hold
1,358
﹤0.01% 3024
2024
Q2
$31K Buy
1,358
+5
+0.4% +$117 ﹤0.01% 2814
2024
Q1
$33K Buy
+1,353
New +$31.7K ﹤0.01% 2576
2022
Q1
Sell
-830
Closed -$36K 3669
2021
Q4
$36K Buy
+830
New +$39.3K ﹤0.01% 1709
2021
Q2
$359K Hold
6,900
﹤0.01% 740
2021
Q1
$359K Hold
6,900
﹤0.01% 740
2020
Q4
$359K Hold
6,900
﹤0.01% 740
2020
Q3
$359K Hold
6,900
﹤0.01% 740
2020
Q2
$359K Hold
6,900
﹤0.01% 740
2020
Q1
$359K Hold
6,900
﹤0.01% 740
2019
Q4
$359K Hold
6,900
﹤0.01% 740
2019
Q3
$359K Hold
6,900
﹤0.01% 740
2019
Q2
$359K Buy
+6,900
New +$182K ﹤0.01% 740

Other funds holding IDNA

Carson Wealth (CWM LLC)'s IDNA Position: Q2 2025 in Review

Carson Wealth (CWM LLC) sold out of iShares Genomics Immunology and Healthcare ETF (IDNA) in Q2 2025, closing a stake of 1,361 shares — an estimated $28K sold.

Carson Wealth (CWM LLC) first reported a position in IDNA in Q2 2019 and held it in 15 quarters. The position peaked at $359K in Q2 2021. 47 funds tracked by Wall St. Rank hold IDNA as of Q2 2025.

  • Carson Wealth (CWM LLC) reported no remaining iShares Genomics Immunology and Healthcare ETF position as of Q2 2025 after selling out during the quarter.
  • Carson Wealth (CWM LLC) sold 1,361 iShares Genomics Immunology and Healthcare ETF shares in Q2 2025, an estimated $28K.
  • Carson Wealth (CWM LLC) first reported a position in iShares Genomics Immunology and Healthcare ETF in Q2 2019 and held it in 15 quarters.
  • Carson Wealth (CWM LLC)'s iShares Genomics Immunology and Healthcare ETF position peaked at $359K in Q2 2021.
  • 47 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2025.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q2 2025, filed 25 Jul 2025.